Form 4: Ligand Pharmaceuticals Director Nancy Ryan Gray Reports Acquisition of Stock Options and Restricted Stock Units

Director Nancy Ryan Gray reports acquisition of stock options and restricted stock units in Ligand Pharmaceuticals.

Summary

• On June 14, 2024, Nancy Ryan Gray, a director of Ligand Pharmaceuticals, acquired 1,252 restricted stock units (RSUs) and 5,444 non-qualified stock options.
• The RSUs were granted by the Board of Directors at their annual meeting and represent a contingent right to receive one share of Ligand's common stock each.
• The RSUs fully vest on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date.
• The non-qualified stock options have an exercise price of $80.06 and also vest on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date, expiring on June 14, 2034.
• Following these transactions, Gray directly owns 6,885 shares of common stock and 5,444 non-qualified stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The document reports a standard equity grant to a director, which is generally viewed as a positive sign of aligning interests with shareholders. There are no indications of negative news or concerns.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and contribution to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the granted securities.

Industry Context

This type of equity grant is a common practice in the pharmaceutical industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company. Grants are typically benchmarked against peer companies to ensure competitiveness.

Comparison to Industry Standards

• Equity grants to directors are a standard practice across publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Companies like Amgen, Gilead Sciences, and Biogen often use similar equity-based compensation to align director and shareholder interests.
• The size and vesting schedule of these grants are usually benchmarked against industry peers to ensure competitiveness and retention.

Stakeholder Impact

• The equity grant aligns the director's interests with those of the shareholders, potentially leading to decisions that benefit the company's long-term value.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates